The success of neoadjuvant immunotherapy trials like Niagara and those with EV-Pembro means most patients will receive immune therapy before surgery. This fundamentally shifts the clinical landscape, making the question of starting adjuvant immunotherapy less relevant as perioperative treatment becomes the standard.

Instead of basing adjuvant radiation decisions on a patient's initial, pre-treatment tumor stage, clinicians should use the post-neoadjuvant pathological stage (ypTNM). Patients with a major pathologic response (e.g., downstaging from T3 to T1) may be able to safely avoid additional adjuvant radiation therapy.

Dr. Ramalingam describes a nuanced clinical approach based on early NEO ADORA data: using neoadjuvant chemo-osimertinib for N2 positive (Stage 3A) patients, but favoring upfront surgery followed by adjuvant therapy for Stage 2. This shows how specialists apply preliminary findings before they become universal standards.

A powerful counseling technique for complex adjuvant therapy decisions is to ask patients: "If your cancer recurs, will you look back and regret the choice you're making today?" This forces patients to confront their own risk tolerance and helps them commit to a treatment path.

A significant real-world barrier to implementing superior neoadjuvant immunotherapy strategies is the referral pattern in community settings. Medical oncologists often don't see patients until after surgery is completed, by which point the opportunity to give neoadjuvant treatment and potentially avoid chemotherapy or major surgery has been lost.

Patients are often exhausted after primary treatment and surprised by the recommendation for two additional years of intensive oral therapy. Clinicians should introduce this possibility early in the treatment journey to manage expectations and prevent the patient from feeling overwhelmed later on.

By improving response rates before surgery, adding intravesical BCG can reduce the number of patients requiring follow-up adjuvant systemic therapy. This de-escalation strategy limits patients' overall exposure to toxic treatments and their side effects, a key benefit beyond improving primary outcomes.

Clinical trial data suggests immunotherapy's timing is crucial in early-stage TNBC. Given with chemotherapy before surgery (neoadjuvant), it improves outcomes. However, when given alone after surgery (adjuvant), the IMPASSION 030 trial showed no benefit and was halted for futility, indicating pre-surgical tumor priming is essential.

Instead of presenting the entire treatment plan upfront, clinicians introduce the Amphorte regimen (lurbinectedin maintenance) after 2-3 cycles of induction chemo-IO, once a patient has shown a response. This avoids overwhelming patients on day one and allows for a more focused discussion when the decision is relevant.